Basic HTML Version
73
Δ. Δ. Κόκκινος και συν. Η χρήση των υπερηχογραφικών σκιαγραφικών ουσιών στη διερεύνηση των παθήσεων της χοληδόχου κύστεως
lesions. Eur Radiol 2011; 21: 457–462.
14. Wilson SR, Burns PN. Microbubble-enhanced US
in body imaging: what role? Radiology 2010; 257:
24-39.
15. Burns PN, Wilson SR, Simpson DH. Pulse inversion
imaging of liver blood flow: improved method
for characterizing focal masses with microbubble
contrast. Invest Radiol 2000; 35: 58-71.
16. Kitzman DW, Goldman ME, Gillam LD et al. Efficacy
and safety of the novel ultrasound contrast agent
perflutren (definity) in patients with suboptimal
baseline left ventricular echocardiographic images.
Am J Cardiol 2000; 86(6): 669-674.
17. Piscaglia F, Bolondi L. Italian Society for Ultrasound
in Medicine and Biology (SIUMB) Study Group on
Ultrasound Contrast Agents. The safety of Sonovue
in abdominal applications: retrospective analysis of
23188 investigations. Ultrasound Med Biol 2006;
32(9): 1369-1375.
18. Internat ional Col laborat ive Study of Severe
Anaphylaxis. Risk of anaphylaxis in a hospital
population in relation to the use of various drugs:
an international study. Pharmacoepidemiol Drug
Saf 2003; 12(3): 195-202.
19. Cochran ST, Bomyea K, Sayre JW. Trends in adverse
events after IV administration of contrast media. AJR
Am J Roentgenol 2001; 176(6): 1385-1388.
20. Main ML, Goldman JH, Grayburn PA. Thinking
Outside the “Box”-The Ul trasound Contrast
Controversy JACC 2007; 50(25): 2434-2437.
21. US Food and Drug Administration. Micro-bubble
contrast agents (marketed as Definity (perflutren
l ipid microsphere) injectable suspension and
Optison (perflutren protein-type A microspheres for
injection). US Food and Drug Administration 2008;
Silver Spring, MD. USA. http://www.fda.gov/Safety/
MedWatch/SafetyInformation/ SafetyAlertsforHuma
nMedicalProducts/ucm092270.htm. Πρόσβαση στις
6/4/2012.
22. Updated safety information on Definity (perflutren
injectablesuspension).HealthCanada2008.Ottawa,
Ontario, Canada. http://www.hc-sc.gc.ca/dhp-mps/
medeff/advisories-avis/prof/_2008/ definity_hpc-
cps_2-eng.php. Πρόσβαση στις 6/4/2012.
23. BurnsPN.Harmonicimagingwithultrasoundcontrast
agents. Clin Radiol 1996; 51(suppl): 50–55.
24. Kumagai Y, Kotanagi H, Ishida H, et al. Gallbladder
adenoma: report of a case with emphasis on contrast-
enhanced US findings. Abdom Imaging 2006; 31:
449–452.
25. Soiva M, Aro K, Pamilo M, et al. Ultrasonography
in carcinoma of the gallbladder. Acta Radiol 1987;
28: 711–714.
26. Sun XJ, Shi JS, Han Y, et al. Diagnosis and treatment
of polypoid lesions of the gallbladder: report of 194
cases. Hepatobiliary Pancreat Dis Int 2004; 3: 591–
594.
27. Way LW, Sleisenger MH. Biliary obstruction,
cholangitis and choledocholithiasis. In: Sleisenger
MH, Fordtran JS, eds. Gastrointestinal Disease. WB
Saunders Co, Philadelphia, 1989.
28. Pitt HA, Dooley WC, Yeo CJ, et al. Malignancies of
the biliary tree. Curr Probl Surg 1995; 32(1): 1-90.
29. Piehler JM, Crichlow RW. Primary carcinoma of
the gallbladder. Surg Gynecol Obstet 1978; 147(6):
929-942.
30. Thorel ius L. Contrast-enhanced ul trasound:
beyond the liver. Eur Radiol 2003; 13 (Suppl 3):
N91-N108.
31. Liu LN, Xu HX, Lu MD, et al. Contrast-Enhanced
Ul t rasound in the Diagnos i s of Gal lbladder
Di seases: A Mul t i -Center Exper ience. PLoS
One. 2012;7(10):e48371. doi: 10.1371/journal.
pone.0048371. Epub 2012 Oct 31.
32. Xie XH, Xu HX, Xie XY, et al. Differential diagnosis
between benign and malignant gallbladder diseases
with real-time contrast-enhanced ultrasound. Eur
Radiol 2010; 20(1): 239-248.
33. Zechner PM, Rienmüller S, Dorr K, et al. Contrast-
enhanced ultrasound detects gallbladder perforation
in a patient with acute abdominal pain. Am J Emerg
Med 2012; 30(3): 516.e5-6.
34. Numata K, Oka H, Morimoto M, et al. Differential
diagnosis of gallbladder diseases with contrast-
enhanced harmonic gray scale ultrasonography. J
Ultrasound Med 2007; 26: 763–774.
35. HirookaY,NaitohY,GotoH, etal.Contrast enhanced
endoscopic ultrasonography in gallbladder diseases.
Gastrointest Endosc 1998; 48: 406–410.
36. Piscaglia F, Nolsøe C, Dietrich CF, et al. The
EFSUMB Guidelines and Recommendations on the
Clinical Practice of Contrast Enhanced Ultrasound
(CEUS): update 2011 on non-hepatic applications.
Ultraschall Med 2012; 33(1): 33-59.